DR. AVANTIKA SRIVASTAVA

DR. AVIK DEY SARKAR, DR. PRATIROOP GANGOPADHYAY, Dr. SANJAY KUMAR DAULAT THAKUR

Abstract

Objective: To compare Macular Thickness (MT) in patients with Non-Proliferative Diabetic Retinopathy (NPDR) with Clinically Significant Macular Edema (CSME) after receiving Intravitreal Ranibizumab following Monthly, PRN protocol and Treat and Extend (T&E). Method: Among 81 patients with NPDR with CSME, 27 received Intravitreal Ranibizumab Monthly (Group A), 27 followed PRN (Group B) and 27 followed T&E protocol (Group C). MT was measured pre-operatively and followed up for 6 months after last injection using Spectral Domain Optical Coherence Tomography. Result: In Group A, the change in MT was 206.74±73.25µm. Group B had a change in MT of 123.59±63.05µm and in Group C it was 194.07±66.16µm. The average injections required for PRN was 6.2; for T&E was 5.03; for monthly it was 9. Conclusion: The change in MT is more in Group A than in Group B (p=0.012). Group C was superior to Group B as well (p=0.036); while there was no significant difference between Group A and Group C (p=0.85).